SOURCE: Dako Denmark A/S

April 24, 2008 06:01 ET

Dako introduces unique package of ready-to-use antibodies for cancer diagnostics

GLOSTRUP, DENMARK--(Marketwire - April 24, 2008) - Dako's new set of ready-to-use antibodies, Flex RTU, is the largest and most clinically relevant antibody portfolio on the market. It has been developed for diagnosis of the most common types of cancer (breast, colon, lung, prostate, melanoma, etc.).

With the number of patients waiting for cancer diagnosis continually on the rise, Dako works to provide pathology laboratories with workflow solutions linking knowledge, reagents, instruments and software for fast and accurate answers.

The set of 61 new, ready-to-use antibodies, Flex RTU, has been designed to deliver:

* unique staining performance through collaboration with leading international pathologists

* improved laboratory efficiency by reducing hands-on time and improving system efficiency

* increased productivity by speeding up the process from test to diagnosis

* increased patient safety due to fewer errors.

Product features:

* State-of-the art staining quality

* Single protocol with user-defined staining intensity

* Improved performance of Dako Autostainer classic and Autostainer Link instruments

* Increased laboratory productivity

* Reagent traceability from start to end of workflow process

* Workflow integration with the power of parallel processing

The first wave of 61 Flex RTU antibodies and 2 negative controls is available now.

For more product information please visit

Media contact:
Dako Group
Maia Fredtoft Søchting
Corporate Communications
+45 25 46 10 83

Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's know-how, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1000 people and operating in more than 70 countries, Dako covers essentially all of the global anatomic pathology markets. Dako is owned by a private equity fund, EQT.

Press release:

Copyright © Hugin AS 2008. All rights reserved.

Contact Information